BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 28139399)

  • 1. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue.
    Ako S; Nouso K; Kinugasa H; Dohi C; Matushita H; Mizukawa S; Muro S; Akimoto Y; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Tsutsumi K; Kato H; Okada H
    Pancreatology; 2017; 17(2):285-290. PubMed ID: 28139399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of KRAS Mutations in Circulating Tumor DNA by Digital PCR in Early Stages of Pancreatic Cancer.
    Brychta N; Krahn T; von Ahsen O
    Clin Chem; 2016 Nov; 62(11):1482-1491. PubMed ID: 27591291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of
    Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
    World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
    Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
    Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer Patients.
    Olmedillas López S; García-Olmo DC; García-Arranz M; Guadalajara H; Pastor C; García-Olmo D
    Int J Mol Sci; 2016 Apr; 17(4):484. PubMed ID: 27043547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
    Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
    BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple KRAS mutations in pancreatic adenocarcinoma: molecular features of neoplastic clones indicate the selection of divergent populations of tumor cells.
    Visani M; de Biase D; Baccarini P; Fabbri C; Polifemo AM; Zanini N; Pession A; Tallini G
    Int J Surg Pathol; 2013 Dec; 21(6):546-52. PubMed ID: 23426962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
    Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
    Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Multiplex Droplet Digital PCR Assay to Identify and Quantify KRAS Mutations in Clinical Specimens.
    Alcaide M; Cheung M; Bushell K; Arthur SE; Wong HL; Karasinska J; Renouf D; Schaeffer DF; McNamara S; Tertre MCD; Batist G; Kennecke HF; Karsan A; Morin RD
    J Mol Diagn; 2019 Mar; 21(2):214-227. PubMed ID: 30472330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control.
    Le Calvez-Kelm F; Foll M; Wozniak MB; Delhomme TM; Durand G; Chopard P; Pertesi M; Fabianova E; Adamcakova Z; Holcatova I; Foretova L; Janout V; Vallee MP; Rinaldi S; Brennan P; McKay JD; Byrnes GB; Scelo G
    Oncotarget; 2016 Nov; 7(48):78827-78840. PubMed ID: 27705932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer.
    Kinugasa H; Nouso K; Miyahara K; Morimoto Y; Dohi C; Tsutsumi K; Kato H; Matsubara T; Okada H; Yamamoto K
    Cancer; 2015 Jul; 121(13):2271-80. PubMed ID: 25823825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of mutant KRAS and TP53 DNA in circulating exosomes from healthy individuals and patients with pancreatic cancer.
    Yang S; Che SP; Kurywchak P; Tavormina JL; Gansmo LB; Correa de Sampaio P; Tachezy M; Bockhorn M; Gebauer F; Haltom AR; Melo SA; LeBleu VS; Kalluri R
    Cancer Biol Ther; 2017 Mar; 18(3):158-165. PubMed ID: 28121262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer.
    Ako S; Kato H; Nouso K; Kinugasa H; Terasawa H; Matushita H; Takada S; Saragai Y; Mizukawa S; Muro S; Uchida D; Tomoda T; Matsumoto K; Horiguchi S; Nobuoka D; Yoshida R; Umeda Y; Yagi T; Okada H
    Cancer Biol Ther; 2021 Dec; 22(10-12):564-570. PubMed ID: 34632919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
    Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
    J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?
    Kim ST; Chang WJ; Jin L; Sung JS; Choi YJ; Kim YH
    Cancer Res Treat; 2015 Oct; 47(4):796-803. PubMed ID: 25687873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
    Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
    Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Pancreatic Juice Collection Time on the Detection of KRAS Mutations.
    Suenaga M; Dudley B; Karloski E; Borges M; Irene Canto M; Brand RE; Goggins M
    Pancreas; 2018 Jan; 47(1):35-39. PubMed ID: 29200129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.